How to cite item

Clinical outcomes and prognostic factors of transcatheter aortic valve implantation in bicuspid aortic valve patients

  
@article{ACS16398,
	author = {Sung-Han Yoon and Rahul Sharma and Tarun Chakravarty and Hiroyuki Kawamori and Yoshio Maeno and Masaki Miyasaka and Takahiro Nomura and Tomoki Ochiai and Sharjeel Israr and Tanya Rami and Mamoo Nakamura and Wen Chen and Raj R. Makkar},
	title = {Clinical outcomes and prognostic factors of transcatheter aortic valve implantation in bicuspid aortic valve patients},
	journal = {Annals of Cardiothoracic Surgery},
	volume = {6},
	number = {5},
	year = {2017},
	keywords = {},
	abstract = {Background: The purpose of this study was to evaluate the outcomes of transcatheter aortic valve replacement (TAVR) in patients with bicuspid aortic valve stenosis (AS).
Methods: From April 2012 and December 2016, 108 patients with bicuspid AS underwent TAVR using the Sapien XT (34 patients) and Sapien 3 (74 patients) valves. Procedural and clinical outcomes were assessed according to VARC-2 criteria and compared between the two devices.
Results: In the overall cohort, the majority of patients were male (71.3%) with an intermediate surgical risk and a mean Society of Thoracic Surgeons (STS) score of 5.2%. Compared to the Sapien XT group, the Sapien 3 group had a significantly lower STS score (3.3%±2.0% vs. 6.7%±3.6%; P=0.001). Compared to the Sapien XT group, the Sapien 3 group had a significantly lower rate of moderate or severe paravalvular leak (2.7% vs. 14.7%; P=0.03) and higher device success (97.3% vs. 82.4%; P=0.006). There were no significant differences between the two groups in terms of 30-day all-cause mortality, stroke, life-threatening bleeding, major vascular complication and acute kidney injury (stage 2 or 3). Cumulative all-cause mortality at 1-year follow-up was 6.9%. There were no significant differences in cumulative event rates for all-cause mortality at 1-year follow-up between the two groups (9.4% vs. 4.6%; log-rank P=0.47). By univariate analysis, major vascular complication was significantly associated with overall all-cause mortality [hazard ratios (HR): 7.57; 95% confidence interval (CI): 1.51–37.86; P=0.014].
Conclusions: TAVR using the balloon-expandable valves provided acceptable procedural and clinical outcomes in patients with bicuspid AS. The new-generation Sapien 3 valves showed improved procedural outcomes compared to the early-generation Sapien XT valves.},
	issn = {2225-319X},	url = {http://www.annalscts.com/article/view/16398}
}